Tag - BTAI

Developments

BioXcel BXCL501 meets primary and secondary endpoints in two Phase 3 trials

BioXcel Therapeutics’ (NASDAQ:BTAI) BXCL501, a dexmedetomidine sublingual thin film, met its primary and secondary endpoints in two Phase 3 trials in patients with schizophrenia and bipolar disorders. In the SERENITY I...

July 20, 2020

Developments

BioXcel initiates Phase 2 hormone-refractory prostate cancer trial

BioXcel Therapeutics (NASDAQ:BTAI) initiated the Phase 2 efficacy portion of its Phase 1b/2 trial of BXCL701, in combination with pembrolizumab, an immunotherapy, for treatment emergent neuroendocrine prostate cancer...

April 28, 2020

Tag - BTAI

BioXcel BXCL501 meets primary and secondary endpoints in two Phase 3 trials

BioXcel initiates Phase 2 hormone-refractory prostate cancer trial

General

More